Cited 52 times in
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김재훈 | - |
dc.date.accessioned | 2015-05-19T17:09:11Z | - |
dc.date.available | 2015-05-19T17:09:11Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/107601 | - |
dc.description.abstract | PURPOSE: Novel biomarkers are urgently needed to increase the sensitivity of CA125 for the early detection of ovarian cancer. Indeed, it has been shown that as much as 20% of early-stage patients do not express significant levels of this biomarker. Therefore, the possibility of using autoantibodies directed against tumor-associated antigens as putative cancer markers is being more examined. Indeed, many autoantibodies have recently been shown to correlate with cancer patient prognosis or to be suitable for detection of the disease. EXPERIMENTAL DESIGN: In this study, we have used a new approach involving the use of proteomics, immunology, and ELISA methods to identify relevant autoantibodies in the plasma of ovarian cancer patients. To do so, we developed an innovative technique called two-dimensional differential gel electrophoresis analysis of immunoprecipitated tumor antigens. RESULTS: This strategy allowed us to successfully identify novel circulating autoantibodies directed against the S100A7 protein in the plasma of ovarian cancer patients. Further real-time reverse transcription-PCR and immunohistochemical studies confirmed that the S100A7 mRNA and protein were highly expressed in ovarian tumors but absent in normal and benign tissues. Moreover, a preliminary study involving 138 patients confirmed that the plasma levels of anti-S100A7 antibodies are significantly elevated in early- and late-stage ovarian cancer patients compared with healthy controls and with patients with benign gynecologic diseases. CONCLUSIONS: This shows that our approach is a valuable tool to successfully identify autoantibodies and tumor-associated antigens in cancer patients and that future research assessing their putative clinical usefulness would be worthwhile. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 764~771 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antigens, Neoplasm/blood* | - |
dc.subject.MESH | Antigens, Neoplasm/genetics | - |
dc.subject.MESH | Antigens, Neoplasm/immunology | - |
dc.subject.MESH | Autoantibodies/blood* | - |
dc.subject.MESH | Autoantibodies/genetics | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Electrophoresis, Gel, Two-Dimensional | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin G/blood | - |
dc.subject.MESH | Ovarian Neoplasms/blood | - |
dc.subject.MESH | Ovarian Neoplasms/genetics | - |
dc.subject.MESH | Ovarian Neoplasms/immunology* | - |
dc.subject.MESH | RNA, Messenger/genetics | - |
dc.subject.MESH | RNA, Neoplasm/genetics | - |
dc.subject.MESH | Reverse Transcriptase Polymerase Chain Reaction | - |
dc.title | Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Audrey Gagnon | - |
dc.contributor.googleauthor | Jae-Hoon Kim | - |
dc.contributor.googleauthor | John O. Schorge | - |
dc.contributor.googleauthor | BinYe | - |
dc.contributor.googleauthor | Brian Liu | - |
dc.contributor.googleauthor | Kathleen Hasselblatt | - |
dc.contributor.googleauthor | William R.Welch | - |
dc.contributor.googleauthor | Christina A. Bandera | - |
dc.contributor.googleauthor | Samuel C. Mok | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-0856 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00876 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 18245537 | - |
dc.subject.keyword | Antigens, Neoplasm/blood* | - |
dc.subject.keyword | Antigens, Neoplasm/genetics | - |
dc.subject.keyword | Antigens, Neoplasm/immunology | - |
dc.subject.keyword | Autoantibodies/blood* | - |
dc.subject.keyword | Autoantibodies/genetics | - |
dc.subject.keyword | Cell Line, Tumor | - |
dc.subject.keyword | Electrophoresis, Gel, Two-Dimensional | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Immunoglobulin G/blood | - |
dc.subject.keyword | Ovarian Neoplasms/blood | - |
dc.subject.keyword | Ovarian Neoplasms/genetics | - |
dc.subject.keyword | Ovarian Neoplasms/immunology* | - |
dc.subject.keyword | RNA, Messenger/genetics | - |
dc.subject.keyword | RNA, Neoplasm/genetics | - |
dc.subject.keyword | Reverse Transcriptase Polymerase Chain Reaction | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 14 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 764 | - |
dc.citation.endPage | 771 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.14(3) : 764-771, 2008 | - |
dc.identifier.rimsid | 53332 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.